60 Degrees PharmaceuticalsSXTP 44 Return-on-Tangible-Asset is -143.30% as of Mar. 2026. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $2.03 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, 60 Degrees Pharmaceuticals ranks worse than 85.17% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. 60 Degrees Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was $-8.36 Mil. 60 Degrees Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was $5.83 Mil. Therefore, 60 Degrees Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -143.30%.
The historical rank and industry rank for 60 Degrees Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
SXTP'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -511.33 Med: -128.94 Max: -86.67
Current: -135.01
During the past 6 years, 60 Degrees Pharmaceuticals's highest Return-on-Tangible-Asset was -86.67%. The lowest was -511.33%. And the median was -128.94%.
SXTP's Return-on-Tangible-Asset is ranked worse than 85.17% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs SXTP: -135.01
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
60 Degrees Pharmaceuticals Return-on-Tangible-Asset Related Terms
60 Degrees Pharmaceuticals Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SXTP vs GLMD, FBLG, CELZ: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
60 Degrees Pharmaceuticals Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where 60 Degrees Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -143.30% mean?
60 Degrees Pharmaceuticals (SXTP) has a Return-on-Tangible-Asset of -143.30% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on 60 Degrees Pharmaceuticals and its competitors. According to the industry distribution chart, 60 Degrees Pharmaceuticals ranks #1206 out of 1416 companies in the Biotechnology industry, placing it in the top 85.2%.
Is 60 Degrees Pharmaceuticals' Return-on-Tangible-Asset too high?
60 Degrees Pharmaceuticals' current Return-on-Tangible-Asset is -143.30%. Based on the distribution chart, 60 Degrees Pharmaceuticals ranks #1206 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' Return-on-Tangible-Asset compare to GLMD and FBLG?
According to the Biotechnology industry distribution chart, 60 Degrees Pharmaceuticals ranks #1206 out of 1416 companies for Return-on-Tangible-Asset. This places 60 Degrees Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on 60 Degrees Pharmaceuticals and its competitors. 60 Degrees Pharmaceuticals's current Return-on-Tangible-Asset is -143.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.03, compared to a current price of $1.55 — trading 23.6% below its estimated fair value. The current Return-on-Tangible-Asset is -143.30%. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current Return-on-Tangible-Asset is -143.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.55 is trading 23.6% below its estimated GF Value™ of $2.03.
GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SXTP:
Return-on-Tangible-Asset: -143.30%
GF Value™: $2.03 vs. price of $1.55 (23.6% below fair value)
No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score
Get the complete analysis for SXTP
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SXTP has been successfully added to your 
